PALISADE BIO, INC. Amortization of Intangible Assets
PALISADE BIO, INC. (PALI) reported Amortization of Intangible Assets of $63.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2021-03-22
- PALISADE BIO, INC. amortization of intangible assets for fiscal 2020 was $63.00K, a 33.68% decline from fiscal 2019.
- PALISADE BIO, INC. amortization of intangible assets for fiscal 2019 was $95.00K, a 6.86% decline from fiscal 2018.
- PALISADE BIO, INC. amortization of intangible assets for fiscal 2018 was $102.00K, a 46.03% decline from fiscal 2017.
- PALISADE BIO, INC. amortization of intangible assets for fiscal 2017 was $189.00K, a 7.39% increase from fiscal 2016.
| Period end | Amortization of Intangible Assets 12 month |
|---|---|
| 2020-12-31 | $63.00K 10-K · filed 2021-03-22 |
| 2019-12-31 | $95.00K 10-K · filed 2021-03-22 |
| 2018-12-31 | $102.00K 10-K · filed 2020-03-27 |
| 2017-12-31 | $189.00K 10-K · filed 2019-03-22 |
| 2016-12-31 | $176.00K 10-K · filed 2018-04-02 |
| 2015-12-31 | $197.00K 10-K · filed 2017-03-23 |
| 2014-12-31 | $211.00K 10-K · filed 2016-03-14 |
| 2013-12-31 | $119.00K 10-K · filed 2016-03-14 |
| 2012-12-31 | $110.00K 10-K · filed 2015-03-16 |
| 2011-12-31 | $83.00K 10-K · filed 2014-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |